Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 15/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5571804 | 1.00 | TNFRSF1A (1.00) | TNFRSF1AABCG2ABCB1 | |
| SCHEMBL6040597 | 0.91 | TNFRSF1A (0.83) | TNFRSF1AABCG2 | |
| SCHEMBL6040592 | 0.91 | TNFRSF1A (0.83) | TNFRSF1AABCG2 | |
| SCHEMBL5960658 | 0.91 | TNFRSF1A (0.83) | TNFRSF1AABCG2 | |
| SCHEMBL5960657 | 0.91 | TNFRSF1A (0.83) | TNFRSF1AABCG2 | |
| SCHEMBL5574888 | 0.90 | TNFRSF1A (1.00) | TNFRSF1AABCB1 | |
| SCHEMBL5574886 | 0.90 | TNFRSF1A (1.00) | TNFRSF1AABCB1 | |
| SCHEMBL4727940 | 0.90 | TNFRSF1A (0.81) | TNFRSF1AABCG2 | |
| SCHEMBL4727944 | 0.90 | TNFRSF1A (0.81) | TNFRSF1AABCG2 | |
| SCHEMBL6040869 | 0.90 | TNFRSF1A (0.81) | TNFRSF1AABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060258735-A1 | 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | MENG CHARLES Q | 2006-11-16 | — | — | US | claimed |
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS PHARMACEUTICALS, INC. | 2003-12-25 | — | — | US | claimed |
| US-6608101-B1 | Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; | ATHEROGENICS, INC. | 2003-08-19 | — | — | US | claimed |
| US-7247714-B2 | Protection against oxidative stress and inflammation by a cytoprotective response element | ATHEROGENICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247714-B2 | Protection against oxidative stress and inflammation by a cytoprotective response element | ATHEROGENICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247714-B2 | Protection against oxidative stress and inflammation by a cytoprotective response element | ATHEROGENICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20060258735-A1 | 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | MENG CHARLES Q | 2006-11-16 | — | — | US | disclosed |
| US-7078431-B2 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20040023233-A1 | Protection against oxidative stress and inflammation by a cytoprotective response element | CRABTREE ACQUISITION CO, LLC | 2004-02-05 | — | — | US | disclosed |
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS PHARMACEUTICALS, INC. | 2003-12-25 | — | — | US | disclosed |
| US-6608101-B1 | Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; | ATHEROGENICS, INC. | 2003-08-19 | — | — | US | disclosed |
| WO-2003033662-A2 | PROTECTION AGAINST OXIDATIVE STRESS AND INFLAMMATION BY A CYTOPROTECTIVE RESPONSE ELEMENT | ATHEROGENICS, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023233-A1 | Protection against oxidative stress and inflammation by a cytoprotective response element | ATF4, HSF1, DDIT3 | TNFRSF1A 1169/4885ABCG2 4478/4885ABCB1 3821/4885 |
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | VCAM1, ICAM1, ITGB1 | TNFRSF1A 183/4885ABCG2 2245/4885ABCB1 752/4885 |
| US-20060258735-A1 | 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | VCAM1, ICAM1, ITGB1 | TNFRSF1A 183/4885ABCG2 2245/4885ABCB1 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.